References
- Chumpitazi, C. E., Rees, C. A., Camp, E. A., & Bernhardt, M. B. (2017). Decreased opioid prescribing in a pediatric emergency department after the rescheduling of hydrocodone. The Journal of Emergency Medicine, 52(4), 547–553. https://doi.org/https://doi.org/10.1016/j.jemermed.2016.08.026
- Dasgupta, N., Bailey, J. E., & Dart, R. C. (2017). Implications of declining poison center case volume on drug abuse trend monitoring (RADARS® System Technical Report, 2017-Q3). https://www.radars.org/system/publications/2017%203Q%20QTR.pdf
- Drug Enforcement Administration. (2018). Hydrocodone. U.S. Department of Justice. https://www.deadiversion.usdoj.gov/drug_chem_info/hydrocodone.pdf#search=hydrocodone
- Drug Enforcement Administration. (2014). Schedules of controlled substances: rescheduling of hydrocodone combination products from Schedule III to Schedule II. U.S. Department of Justices Federal Register. https://www.federalregister.gov/documents/2014/08/22/2014-19922/schedules-of-controlled-substances-rescheduling-of-hydrocodone-combination-products-from-schedule
- Gummin, D. D., Mowry, J. B., Spyker, D. A., Brooks, D. E., Beuhler, M. C., Rivers, L. J., Hashem, H. A., & Ryan, M. L. (2019). 2018 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 36th Annual report. Clinical Toxicology (Philadelphia, Pa.), 57(12), 1220–1413. https://doi.org/https://doi.org/10.1080/15563650.2019.1677022
- Haynes, A., Kleinschmidt, K., Forrester, M. B., & Young, A. (2016). Trends in analgesic exposures reported to Texas Poison Centers following increased regulation of hydrocodone. Clinical Toxicology (Philadelphia, Pa.), 54(5), 434–440. https://doi.org/https://doi.org/10.3109/15563650.2016.1148720
- IQVIATM (2019). (Danbury, CT), US-based longitudinal prescription data.
- Jones, C. M., Lurie, P. G., & Throckmorton, D. C. (2016). Effect of US drug enforcement administration’s rescheduling of hydrocodone combination analgesic products on opioid analgesic prescribing. JAMA Internal Medicine, 176(3), 399–402. https://doi.org/https://doi.org/10.1001/jamainternmed.2015.7799
- Murimi, I. B., Chang, H. Y., Bicket, M., Jones, C. M., & Alexander, G. C. (2019). Using trajectory models to assess the effect of hydrocodone upscheduling among chronic hydrocodone users. Pharmacoepidemiology and Drug Safety, 28(1), 70–79. https://doi.org/https://doi.org/10.1002/pds.4639
- Oehler, E. C., Day, R. L., Robinson, B. H. A., & Brown, L. H. (2016). Has the rescheduling of hydrocodone changed ED prescribing practices? The American Journal of Emergency Medicine, 34(12), 2388–2391. https://doi.org/https://doi.org/10.1016/j.ajem.2016.09.002
- Smith, M. Y., Dart, R. C., Hughes, A., Geller, A., Senay, E., Woody, G., & Colucci, S. (2006). Clinician Validation of Poison Control Center (PCC) intentional exposure cases involving prescription opioids. The American Journal of Drug and Alcohol Abuse, 32(3), 465–478. https://doi.org/https://doi.org/10.1080/00952990600753982
- Substance Abuse and Mental Health Services Administration (SAMHSA). (2014). Results from the 2013 National Survey on Drug Use and Health: Detailed tables. https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs2013/NSDUH-DetTabs2013.htm
- United States Drug Enforcement Administration. (2022). Drug scheduling. Retrieved March 9, 2022, from, https://www.dea.gov/drug-information/drug-scheduling
- Wu, A., Phan, C., Nguyen, K. C., Quindoy, M., Lewis, J., & Apollonio, D. E. (2021). Trends in hydrocodone combination product exposures reported to California Poison Control System (CPCS) following DEA rescheduling. Clinical Toxicology (Philadelphia, Pa.), 59(4), 313–319. https://doi.org/https://doi.org/10.1080/15563650.2020.1803350